Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland.
The £400 million ($529 million) investment programme pledged as part of the new voluntary system of rebates paid by pharma companies in the UK has been announced and will focus mainly on su
NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for peop
Thousands of men in the UK with advanced hormone-sensitive prostate cancer could soon be eligible for an oral therapy – Accord Healthcare's Orgovyx – that can be taken at home rather than r
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl